Imugene Ltd has released a press release.
Imugene HER-Vaxx Clinical Trial Collaboration with Merck
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Imugene
- Oncolytic Virotherapy CF33 Patent Granted in Japan
- PD1-Vaxx Clinical Trial Supply Agreement with Roche
- HER-Vaxx Immunotherapy Patent Granted in Europe
- Imugene Receives $6.54 million R&D Tax Incentive
- South Korea HERVaxx Patent Grant
Later from Imugene
- Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
- Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
- Termination of Supply Agreement
- Clarification Announcement
- IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene